0001209191-18-033109.txt : 20180524
0001209191-18-033109.hdr.sgml : 20180524
20180524180502
ACCESSION NUMBER: 0001209191-18-033109
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180522
FILED AS OF DATE: 20180524
DATE AS OF CHANGE: 20180524
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Howton David T
CENTRAL INDEX KEY: 0001529297
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14895
FILM NUMBER: 18859026
MAIL ADDRESS:
STREET 1: VERTEX PHARMACEUTICALS INCORPORATED
STREET 2: 130 WAVERLY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc.
CENTRAL INDEX KEY: 0000873303
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 930797222
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-274-4000
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Sarepta Therapuetics, Inc.
DATE OF NAME CHANGE: 20120712
FORMER COMPANY:
FORMER CONFORMED NAME: AVI BIOPHARMA INC
DATE OF NAME CHANGE: 19980930
FORMER COMPANY:
FORMER CONFORMED NAME: ANTIVIRALS INC
DATE OF NAME CHANGE: 19970123
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-05-22
0
0000873303
Sarepta Therapeutics, Inc.
SRPT
0001529297
Howton David T
215 FIRST STREET, SUITE 415
CAMBRIDGE
MA
02142
0
1
0
0
SVP, General Counsel
Common Stock
2018-05-22
4
M
0
5319
A
36437
D
Common Stock
2018-05-22
4
F
0
1566
89.22
D
34871
D
Restricted Stock Units
2018-05-22
4
M
0
5319
0.00
D
Common Stock
5319
0
D
Restricted stock units convert into common stock on a one-for-one basis.
Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of restricted stock units granted on March 10, 2017.
On March 10, 2017, the reporting person was granted restricted stock units that vest based on the Company's satisfaction of certain performance criteria. The first performance criterion was met on August 3, 2017, resulting in vesting of 50% of such restricted stock units, and the second performance criterion was met on May 22, 2018, resulting in vesting of additional 25% of such restricted stock units.
David Tyronne Howton
2018-05-24